Genetic manipulation of LKB1 elicits lethal metastatic prostate cancer

Ivana Heřmanová(CIC bioGUNE), Arkaitz Carracedo(Ikerbasque), Rosa Barrio(Euskadiko Parke Teknologikoa), Alfredo Caro‐Maldonado(CIC bioGUNE), Ana R. Cortázar(CIC bioGUNE), Marc Núnez-Ollé(Institute for Research in Biomedicine), Verónica Torrano(University of the Basque Country), Mariona Graupera(Josep Carreras Leukaemia Research Institute), Juana M. Flores(Universidad Complutense de Madrid), Bora Gürel(Institute of Cancer Research), Antonio Gómez‐Muñoz(University of the Basque Country), Jan Trka(Charles University), Amaia Zabala‐Letona(BioCruces Health research Institute), Lorea Valcárcel-Jiménez(Tisch Hospital), Iris Lodewijk(Hospital Universitario 12 De Octubre), Mar Lorente(Universidad Complutense de Madrid), José I. López(BioCruces Health research Institute), Anabel Martínez-Romero(Josep Carreras Leukaemia Research Institute), Guillermo Velasco(Instituto de Investigación Sanitaria del Hospital Clínico San Carlos), Ana Talamillo(CIC bioGUNE), Patricia Zúñiga-García(CIC bioGUNE), Laura Camacho(University of the Basque Country), Roger R. Gomis(Institució Catalana de Recerca i Estudis Avançats), Johann S. de Bono(Royal Marsden NHS Foundation Trust), Natalia Martín-Martín(CIC bioGUNE), James D. Sutherland(CIC bioGUNE), Fernando Salvador(Institute for Research in Biomedicine), Sonia Fernández‐Ruiz(CIC bioGUNE), Marc Guiu(Institute for Research in Biomedicine), Ianire Astobiza(University of the Basque Country), Suzanne Carreira(Institute of Cancer Research), Jesús M. Paramio(Universidad Complutense de Madrid), Amaia Arruabarrena-Aristorena(CIC bioGUNE), Cristian Suárez-Cabrera(Research Institute Hospital 12 de Octubre), José M. Lizcano(Universitat Autònoma de Barcelona)
The Journal of Experimental Medicine
March 27, 2020
Cited by 34


Related Papers